Navigation Links
New drug protects against side effects of chemotherapy
Date:1/22/2013

A drug developed at Linkping University in Sweden protects against the side effects of cancer treatments while strengthening the effects on the tumour. An international drug evaluation is now starting up on a larger group of patients.

The results of the studies with the compound, known as calmangafodipir, were published in the latest issue of the cancer journal Translational Oncology with Professor Rolf G. G. Andersson as the main author. The research was initiated on a substance called mangafodipir, which was used as a contrast media in magnetic resonance scans. But pharmacologists at LiU discovered that it also protected healthy cells in connection with cancer treatments.

"We found that the substance could affect the formation of oxygen radicals, which are a cause of side effects in chemotherapy," says Professor Andersson. For example, the number of white blood cells decreases drastically in almost all the patients, which opens the door to infections that could even be fatal.

The researchers began with cell tests, and then went on to mice infected with cancer cells. The mice were treated with chemotherapy and were administered mangafodipir at the same time. Tumour formation decreased while white blood cells were protected. One problem was that a large portion of the manganese in the substance was released; as a consequence, the positive effect subsided. The free manganese can also be poisonous and cause brain damage.

"We remade the substance and replaced a lot of the manganese with calcium. This yielded a more stable complex, which turned out to be even better at protecting cells, thereby increasing the anti-cancer effect," says Professor Andersson. The effect of mangafodipir was confirmed in a smaller study on patients with colon cancer, which was published in Translational Oncology in February 2012.

Jan Olof G. Karlsson is a senior lecturer at Linkping University and a senior researcher at PledPharma AB who is developing the drug, which will be marketed under the brand name PledOx. An international Phase 2 study, involving patients with cancer of the large intestine, has recently been initiated. The results are expected at the end of the year.


'/>"/>

Contact: Rolf G.G. Andersson
rolf.andersson@liu.se
46-070-237-1080
Linkping University
Source:Eurekalert

Related medicine news :

1. Minimal Exercise Protects Senior’s Hearts According to Recent Study Reviewed By Projects for Natural Health Choices Inc.
2. High levels of vitamin D in plasma protects against bladder cancer
3. Aspirin protects against Barretts esophagus
4. Broken heart syndrome protects the heart from adrenaline overload
5. Vitamin E in diet protects against many cancers
6. Voices Against Brain Cancer Responds to a Mother’s Successful Fight Against her Glioblastoma
7. To protect against injuries, young athletes may need to play more just for fun
8. More Focused Radiation Treatment May Work Better Against Brain Tumors
9. Vapor Steam Cleaners Help Protect Puppies Against Canine Parvovirus Disease, Announces 1-800-GO-VAPOR.com
10. Going Online for Info May Reflect a Pro-Active Stance Against Cancer
11. FDA Panel Recommends Against 1st Drug for Chronic Fatigue Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Finn Mouseson”: ... take precedence in an average life. This mouse sets out on a journey that ... heart. “Finn Mouseson” is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, ...
(Date:9/20/2017)... ... ... “The Financial Favor of God; Second Edition”: a personal and exquisite recipe ... creation of published author, Brooks Rathell. , “We typically hear about the favor of ... financial favor of God. Not only does it exist, but it is meant for ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... MD (PRWEB) , ... September 19, 2017 , ... ... the Society of Professional Benefit Administrators (SPBA) hosted “Expanding Your Success” ... for SPBA Members as it focused on best practices for third party administrators ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
(Date:9/12/2017)...  ValGenesis Inc., the global leader in Enterprise ... announce the appointment of Dr. Ajaz Hussain ... Directors and Chairman of Advisory Board beginning September ... to manage their entire validation lifecycle process electronically ... process. Furthermore, ValGenesis VLMS enables rigorous compliance, helps ...
Breaking Medicine Technology: